Chemerin as a novel crevicular fluid marker of patients with periodontitis and type 2 diabetes mellitus

Background: The objectives of the present study are to: 1) determine whether gingival crevicular fluid (GCF) chemerin is a novel predictive marker for patients with chronic periodontitis (CP) with and without type 2 diabetes mellitus (T2DM); 2) analyze the relationship between chemerin and interleukin (IL)-6 in periodontally healthy individuals and in patients with CP and with and without T2DM; and 3) evaluate the effect of non-surgical periodontal therapy on GCF chemerin levels. Methods: Eighty individuals were split into four groups: 20 who were systemically and periodontally healthy (CTRL), 20 with T2DM and periodontally healthy (DM-CTRL), 20 systemically healthy with CP (CP), and 20 with CP and T2DM (DM-CP). Individuals with periodontitis were treated with non-surgical periodontal therapy. GCF sampling procedures and clinical periodontal measures were performed before and 6 weeks after treatment. Enzyme-linked immunosorbent assay was used to measure chemerin and IL-6 levels. Results: Greater values for GCF chemerin and IL-6 levels were found in CP groups than in periodontally healthy groups, inDM-CP than inCP, and in DM-CTRL than inCTRL (P <0.008). GCF chemerin and IL-6 levels decreased following therapy in CP groups (P <0.02). A comprehensive overview of all groups showed a statistically significant positive correlation of chemerin with IL-6, glycated hemoglobin, sampled-site clinical attachment level, and gingival index (P <0.05). Conclusions: In this study, periodontitis and T2DM induced aberrant secretion of chemerin, and non-surgical periodontal therapy influenced the decrease of GCF chemerin levels in patients with CP with and without T2DM. Furthermore, it suggests GCF chemerin levels may be considered a potential proinflammatory marker for diabetes, periodontal disease, and treatment outcomes.

Dergi Adı Journal of Periodontology
Dergi Cilt Bilgisi 87
Dergi Sayısı 8
Sayfalar 923 - 933
Yayın Yılı 2016
Eser Adı
[dc.title]
Chemerin as a novel crevicular fluid marker of patients with periodontitis and type 2 diabetes mellitus
Yazar
[dc.contributor.author]
Dogan S.B.
Yazar
[dc.contributor.author]
Balli U.
Yazar
[dc.contributor.author]
Dede F.O.
Yazar
[dc.contributor.author]
Sertoglu E.
Yazar
[dc.contributor.author]
Tazegül K.
Yayın Yılı
[dc.date.issued]
2016
Yayıncı
[dc.publisher]
American Academy of Periodontology
Yayın Türü
[dc.type]
article
Özet
[dc.description.abstract]
Background: The objectives of the present study are to: 1) determine whether gingival crevicular fluid (GCF) chemerin is a novel predictive marker for patients with chronic periodontitis (CP) with and without type 2 diabetes mellitus (T2DM); 2) analyze the relationship between chemerin and interleukin (IL)-6 in periodontally healthy individuals and in patients with CP and with and without T2DM; and 3) evaluate the effect of non-surgical periodontal therapy on GCF chemerin levels. Methods: Eighty individuals were split into four groups: 20 who were systemically and periodontally healthy (CTRL), 20 with T2DM and periodontally healthy (DM-CTRL), 20 systemically healthy with CP (CP), and 20 with CP and T2DM (DM-CP). Individuals with periodontitis were treated with non-surgical periodontal therapy. GCF sampling procedures and clinical periodontal measures were performed before and 6 weeks after treatment. Enzyme-linked immunosorbent assay was used to measure chemerin and IL-6 levels. Results: Greater values for GCF chemerin and IL-6 levels were found in CP groups than in periodontally healthy groups, inDM-CP than inCP, and in DM-CTRL than inCTRL (P <0.008). GCF chemerin and IL-6 levels decreased following therapy in CP groups (P <0.02). A comprehensive overview of all groups showed a statistically significant positive correlation of chemerin with IL-6, glycated hemoglobin, sampled-site clinical attachment level, and gingival index (P <0.05). Conclusions: In this study, periodontitis and T2DM induced aberrant secretion of chemerin, and non-surgical periodontal therapy influenced the decrease of GCF chemerin levels in patients with CP with and without T2DM. Furthermore, it suggests GCF chemerin levels may be considered a potential proinflammatory marker for diabetes, periodontal disease, and treatment outcomes.
Kayıt Giriş Tarihi
[dc.date.accessioned]
2019-12-23
Açık Erişim Tarihi
[dc.date.available]
2019-12-23
Yayın Dili
[dc.language.iso]
eng
Konu Başlıkları
[dc.subject]
Chemerin protein
Konu Başlıkları
[dc.subject]
Diabetes mellitus
Konu Başlıkları
[dc.subject]
Gingival crevicular fluid
Konu Başlıkları
[dc.subject]
Human
Konu Başlıkları
[dc.subject]
Interleukin-6
Konu Başlıkları
[dc.subject]
Periodontal disease
Konu Başlıkları
[dc.subject]
Periodontitis
Haklar
[dc.rights]
info:eu-repo/semantics/closedAccess
ISSN
[dc.identifier.issn]
0022-3492
İlk Sayfa Sayısı
[dc.identifier.startpage]
923
Son Sayfa Sayısı
[dc.identifier.endpage]
933
Dergi Adı
[dc.relation.journal]
Journal of Periodontology
Dergi Sayısı
[dc.identifier.issue]
8
Dergi Cilt Bilgisi
[dc.identifier.volume]
87
Tek Biçim Adres
[dc.identifier.uri]
https://dx.doi.org/10.1902/jop.2016.150657
Tek Biçim Adres
[dc.identifier.uri]
https://hdl.handle.net/20.500.12628/4645
Görüntülenme Sayısı ( Şehir )
Görüntülenme Sayısı ( Ülke )
Görüntülenme Sayısı ( Zaman Dağılımı )
Görüntülenme
21
09.12.2022 tarihinden bu yana
İndirme
1
09.12.2022 tarihinden bu yana
Son Erişim Tarihi
18 Şubat 2024 16:11
Google Kontrol
Tıklayınız
chemerin levels periodontal groups healthy therapy periodontally periodontitis non-surgical without patients treatment systemically clinical marker diabetes gingival individuals comprehensive overview disease decrease following outcomes decreased proinflammatory inCTRL DM-CTRL inDM-CP values Greater Results considered showed influenced
6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms